LEADER 10966nam 2200613 450 001 9910488707403321 005 20230717102942.0 010 $a981-15-7564-9 035 $a(CKB)5470000000736359 035 $a(MiAaPQ)EBC6665409 035 $a(Au-PeEL)EBL6665409 035 $a(OCoLC)1259591138 035 $a(PPN)260302090 035 $a(EXLCZ)995470000000736359 100 $a20220322d2021 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNanomedicine for cancer diagnosis and therapy /$fArshi Malik, Sarah Afaq and Mohammed Tarique (editors) 210 1$aGateway East, Singapore :$cSpringer,$d[2021] 210 4$d©2021 215 $a1 online resource (251 pages) 311 $a981-15-7563-0 320 $aIncludes bibliographical references. 327 $aIntro -- Contents -- About the Editors -- 1: Nanoparticles for Cancer Therapy -- 1.1 Introduction -- 1.1.1 Cancer and its Types -- 1.1.2 Nanomedicine -- 1.2 Evolution of Cancer Therapy -- 1.2.1 Surgery and Adjuvant Therapies -- 1.2.2 Hormone Therapy -- 1.2.3 Immunotherapy -- 1.2.4 Cancer Therapy with Nanomedicine -- 1.3 Nanoparticles in Cancer Therapy -- 1.3.1 Protein Nanoparticles -- 1.3.2 Magnetic Nanoparticles -- 1.3.3 Inorganic Nanoparticles -- 1.3.4 Lipid Nanoparticles -- 1.3.5 Targeted Nanoparticles -- 1.3.6 Polymeric Nanoparticles -- 1.3.7 Multifunctional Nanoparticles -- 1.3.8 Quantum Dots -- 1.3.9 DNA Nanoparticles -- 1.4 Pharmacokinetics of Cancer Nanodrug Carriers -- 1.5 Cancer Nanomedical Research -- 1.5.1 Initial Advancements in Nanoparticle Research -- 1.5.2 Nanomedical Research Using Plant-Derived Compounds -- 1.5.3 Nanomedical Research Using Gene Therapeutic Strategies -- 1.5.4 Nanomedical Research Using In Vivo Imaging Techniques -- 1.5.5 Mainstream Research in the ``Golden Age´´ of Nanotechnology -- 1.5.6 Nanomedical Research Using Computational and Nanobioinformatic Tools -- 1.6 Nanomedicine in Cancer Diagnosis and Treatment -- 1.6.1 Immunoassays Using Nanomaterial-Embedded Microchips -- 1.6.2 In Vivo Imaging Using Nanoparticle Contrast Agents -- 1.6.3 Theranostic Nanomedicine -- 1.6.4 Cancer Nanodrug Release Systems and Personalized Cancer Nanomedicine -- 1.7 Current Research and Prospects -- 1.7.1 Smart Nanocarrier-Based Drug-Delivery Systems for Cancer Therapy -- 1.7.2 RNA Delivery Using Nanoparticles -- 1.7.3 Nanobots -- 1.8 Concluding Remarks -- References -- 2: Strategies for Improving the Efficiency of Nanomaterials -- 2.1 Introduction -- 2.2 Strategies for the Improvement of Nanomaterials -- 2.2.1 Photocatalytic Efficiency -- 2.2.2 Therapeutic Efficiency. 327 $a2.2.2.1 Strategic Improvement of Nanomaterials for Enhanced Permeability and Retention (EPR) Effects -- 2.2.2.2 Strategic Improvement of Nanomedicine for Improved Drug Delivery Systems -- Liposome Based Nanoformulation -- Nanoemulsions -- Solid Lipid Nanoparticles (SLN) -- Strategies for Organelles Specific Targeting of Nanodrugs -- Virus Based Nanoformulation -- 2.2.2.3 Photoactivated Nanomaterials for Photodynamic and Photothermal Therapy (PDT/PTT) -- 2.2.2.4 Mesoporous Silica Nanoparticles (MSNP) -- 2.2.2.5 Dendrimers -- 2.2.3 Engineering Nanoparticles to Evade the Multidrug Resistance (MDR) in Cancer -- 2.2.4 Nanoparticle-Based Combination Therapy -- 2.3 Conclusion -- References -- 3: Bioinspired Nanoparticles in Cancer Theranostics -- 3.1 Introduction -- 3.2 Novelty of Bioinspired Nanoparticles Based Theranostics -- 3.2.1 Liposomes in Cancer Theranostics -- 3.2.2 Lipid Nanoparticles in Cancer Theragnostic -- 3.2.2.1 Solid Lipid Nanoparticles (SLNs) -- 3.2.2.2 Nano-Structured Lipids (NLCs) -- 3.2.2.3 Lipid Nanocapsules (LNCs) -- 3.2.3 Protein-Based Nanoparticles for Cancer Theranostics -- 3.2.4 Virus like Nanoparticles in Cancer Theranostics -- 3.2.5 Inorganic and Bionanoparticles in Cancer Theranostics -- 3.3 Conclusions and Future Perspectives -- References -- 4: Nanomedicines for Solid Tumors: Current Status, Challenges, and Future Prospects -- 4.1 Introduction -- 4.2 Possible Factors that Initiate Cancer Growth -- 4.2.1 Age -- 4.2.2 Cancer Causing Elements -- 4.2.3 Immunosuppression -- 4.2.4 Infectious Agents -- 4.2.5 Radiation -- 4.3 Tumor Classification Based on Tissue of Origin -- 4.4 Existing Treatment Options Available for Cancer -- 4.5 Description of Solid Tumor -- 4.6 Nanomedicine -- 4.6.1 Unlocking Novel Cancer Applications Exploited in the Field of Nanomedicine -- 4.7 Fabrications of Nanocarrier for Drug Delivery. 327 $a4.8 Targeted Delivery of Nanocarrires to the Tumor Niche as Well as Solid Tumor -- 4.8.1 Drug Targeting Mechanisms and Surface Functionalization of Nanocarriers Aiding Nanomedicine Based Technologies in Solid ... -- 4.9 Nanoscience Based Imaging Technologies in the Detection of Solid Tumors -- 4.9.1 Photodynamic Nanomedicine in the Treatment of Solid Tumors -- 4.10 Nanomedicine and Solid Tumor Heterogenecity -- 4.11 Nanomedicine in Solid Tumors: PROS and CONS? -- 4.11.1 PROS -- 4.11.2 CONS -- 4.12 Discussion -- 4.13 Future Perspective -- References -- 5: Nanomaterials for Early Cancer Diagnostics -- 5.1 Introduction -- 5.2 Cancer and Biomarkers -- 5.2.1 Early Detection of Prostate Cancer -- 5.2.2 Early Detection of Breast Cancer -- 5.2.3 Early Detection of Lung Cancer -- 5.2.4 Early Detection of Liver Cancer -- 5.2.5 Early Detection of Oral Cancer -- 5.2.6 Early Detection of Pancreatic Cancer -- 5.2.7 Early Detection of Ovarian Cancer -- 5.2.8 Early Detection of Human Cervical Cancer -- 5.2.9 Early Detection of Bladder Cancer -- 5.2.10 Early Detection of Head and Neck Cancer -- 5.2.11 Early Detection of Colon Cancer -- 5.3 Conclusion -- References -- 6: Role of Nanomedicine for Cancer Immunotherapy -- 6.1 Introduction -- 6.2 Improving Cellular-Mediated Immunotherapy -- 6.2.1 Combining Therapeutic Agents to Immune Cells -- 6.2.2 Directing Therapeutic Drugs to Immune Cells -- 6.2.3 Delivery of Gene in Lymphocytes -- 6.3 Delivery Mechanism of Nanoparticle Therapeutics -- 6.3.1 Stimulating Immunogenic Cell Death (ICD) -- 6.3.1.1 Nanosized Drug Carriers -- 6.3.1.2 Nanopulse Stimulation -- 6.3.2 Enhanced Presentation of Ligands to Immune Cells -- 6.3.3 Chronological Regulation of Immunostimulation -- 6.4 Modulation in Pharmacokinetics of Immunotherapy Agents -- 6.5 Targeting Myeloid Cells -- 6.6 Targeting Stromal Cell in TME. 327 $a6.7 Limitations of Nanomedicines in Cancer Immunotherapy -- 6.8 Conclusion and Future Perspectives -- References -- 7: Targeting Tumor Microenvironment Through Nanotheranostics -- 7.1 Introduction -- 7.2 The Tumor Microenvironment (TME) and its Components -- 7.2.1 Cells of the Immune System -- 7.2.1.1 The T Cells -- 7.2.1.2 The B Cells -- 7.2.1.3 Tumor Associated Macrophages (TAMs) -- 7.2.1.4 Tumor Associated Neutrophils (TANs) -- 7.2.1.5 Natural Killer (NK) Cells -- 7.2.1.6 Cancer Associated Fibroblasts (CAFs) -- 7.2.2 The Extracellular Matrix (ECM) and Surrounding Cells -- 7.2.2.1 The Adipocytes -- 7.2.2.2 The Pericytes -- 7.2.2.3 Matrix Metalloproteases (MMPs) and Other Proteases -- 7.2.2.4 The Endothelial Cells -- 7.2.3 The TME, Inflammation, and Cancer -- 7.2.4 Hypoxia in the TME -- 7.3 The TME as an Attractive Therapeutic Target in Cancer -- 7.4 Cancer Nanotheranostic Agents that Target the TME -- 7.4.1 Metallic Nanoparticles (NPs) -- 7.4.2 Magnetic Nanoparticles (MNPs) -- 7.4.3 Mesoporous Silica Nanoparticles (MSiNPs) -- 7.4.4 Nano-Graphenes (NGs) -- 7.4.5 Polymeric-Based Nanotheranostic Particles (PNPs) -- 7.4.6 Lipid-Based Nanotheranostic Particles (LNPs) -- 7.4.7 Protein-Based Nanotheranostic Particles (PNPs) -- 7.4.8 Viral-Based Nanotheranostic Particles (VLPs) -- 7.4.9 DNA-Based Cancer Nanotheranostic Platform -- 7.5 Visualizing Cancer Through Nanotheranostics -- 7.5.1 Magnetic Resonance Imaging (MRI) -- 7.5.2 Photoacoustic Imaging (PAI) -- 7.5.3 Optical Imaging -- 7.5.4 Nuclear Imaging -- 7.6 Nanotheranostics for the Detection of Cancer Biomarkers -- 7.6.1 Labeling Nanoparticles with Conjugates -- 7.6.1.1 Chemical Crosslinking -- 7.6.1.2 Biotin/Avidin Conjugation -- 7.6.1.3 Click Chemistry -- 7.6.2 Target Moieties for Identification of Cancer Biomarkers -- 7.7 Conclusion and Future Direction -- References. 327 $a8: Therapeutic Applications of Noble Metal (Au, Ag, Pt)-Based Nanomedicines for Melanoma -- 8.1 Introduction -- 8.1.1 Melanoma -- 8.1.1.1 Global Statistics and Market -- 8.1.1.2 Treatment Strategies -- 8.1.2 Nanotechnology in Melanoma -- 8.1.2.1 Nanoparticles for Melanoma -- 8.1.2.2 PAMAM -- 8.1.2.3 Zinc Oxide Nanoparticle -- 8.1.2.4 Titanium Dioxide Nanoparticle -- 8.1.2.5 Vanadium Pentoxide Nanoparticle -- 8.1.2.6 Copper Prussian Blue Nanoparticle -- 8.2 Importance of Noble Metal Nanoparticles in Biomedicine -- 8.3 Role of Noble Metals (Au, Ag, Pt) in Treatment of Melanoma -- 8.3.1 Gold (Au) Nanoparticles -- 8.3.1.1 Drug Delivery -- 8.3.1.2 Gene Delivery and Immunotherapy -- 8.3.1.3 Biosynthesized Gold Nanoparticles -- 8.3.1.4 Imaging -- 8.3.1.5 Photothermal and Photodynamic Therapy -- 8.3.2 Silver (Ag) Nanoparticles -- 8.3.3 Platinum (Pt) Nanoparticles -- 8.4 Toxicity of Noble Metal Nanoparticles -- 8.5 Challenges and Future Perspectives -- 8.6 Conclusion -- References -- 9: Ethics in Nanomedicine -- 9.1 Introduction -- 9.2 Nanomedicine -- 9.3 Difference Between Nanotechnology and Nanomedicine -- 9.4 Hype Versus Reality of Nanomedicine -- 9.5 Nondiscrimination and Integrity of Nanomedicine -- 9.6 The Potentiality of Nanomedicine -- 9.7 Biocompatibility and Toxicity of Nanostructures -- 9.8 Demand of the Nanomedicine in Market -- 9.9 Nanomedicine and Ethical Concerns -- 9.9.1 Ethical Problems Associated with Translational Research Involving Nanomedicine -- 9.9.2 Ethical Problems in Personalized and Regenerative Therapy with Nanomedicine -- 9.9.3 Ethical Concerns of Medical Surveillance -- 9.9.4 Ethical Challenges Inherent to Nanomedicine Applications -- 9.9.5 Social Ethics in Public Health Systems -- 9.9.5.1 Impact of Nanotechnology in Developing Nations -- 9.9.5.2 Impact of Nanotechnology on Laborers and Managerial Issues. 327 $a9.10 Future Perspectives. 606 $aNanomedicine 606 $aCancer$xTreatment$xTechnological innovations 606 $aNanomedicina$2thub 606 $aOncologia$2thub 606 $aTerapčutica$2thub 608 $aLlibres electrňnics$2thub 615 0$aNanomedicine. 615 0$aCancer$xTreatment$xTechnological innovations. 615 7$aNanomedicina 615 7$aOncologia 615 7$aTerapčutica 676 $a616.994075 702 $aTarique$b Mohammed 702 $aAfaq$b Sarah 702 $aMalik$b Arshi 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910488707403321 996 $aNanomedicine for Cancer Diagnosis and Therapy$92193160 997 $aUNINA